Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 83

Sort by

Sort Order Select

Journal Articles

A Phase 1 Trial of OPB-111077 in Combination with Bendamustine (B) and Rituximab (R) in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of Dose-Escalation Stage

Tomomi Toubai, Junya Kuroda, Youko Suehiro, Yuko Mishima, Kazutaka Sunami, Koji Kato, Nobuhiko Uoshima, Takahiro Kumode, Ai Ota, Kaori Mitsuki, Daisuke Yokota, Yuri Sano, Yasuhito Terui

Blood (2023) 142 (Supplement 1): 4464.

https://doi.org/10.1182/blood-2023-179716

Published: 2023

Journal Articles

Post-Hoc Analysis of the Final, Three-Year Follow-up Results of a Phase I/II Study on Tirabrutinib (ONO-4059) in Patients with Relapsed or Refractory Primary Central Nervous System Lymphoma

Noriko Fukuhara, Yoshitaka Narita, Motoo Nagane, Kazuhiko Mishima, Yasuhito Terui, Yoshiki Arakawa, Hajime Yonezawa, Katsunori Asai, Kazuhiko Sugiyama, Naoki Shinojima, Arata Aoi, Ryo Nishikawa

Blood (2023) 142 (Supplement 1): 4472.

https://doi.org/10.1182/blood-2023-180438

Published: 2023

Journal Articles

Mixture Model to Predict the Cumulative Incidence of Relapses in Follicular Lymphoma : Need for Longer Follow-up or Alternative Outcomes

Blood (2023) 142 (Supplement 1): 7401.

https://doi.org/10.1182/blood-2023-189296

Published: 2023

Journal Articles

The Seven-Color FISH Analysis Can Detect the Acquisition Pattern of Complex Chromosomal Abnormalities Related to Poor Response and Prognosis in Patients with Multiple Myeloma

Yuko Mishima, Yuko Shirouchi, Tomoko Takayama, Sayuri Minowa, Yuko Ishihara, Nobuhiko Yamauchi, Mitsuhito Hirano, Kei Hirano, Kikuaki Yoshida, Yukako Teramoto, Fuka Mima, Yasuhito Terui, Masanori Nojima, Dai Maruyama

Blood (2023) 142 (Supplement 1): 6624.

https://doi.org/10.1182/blood-2023-174437

Published: 2023

Journal Articles

Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial

Blood (2023) 141 (16): 1971–1981.

https://doi.org/10.1182/blood.2022017734

Published: 2023

Includes: Supplemental data

Journal Articles

Quality of Life and Karnofsky Performance Status in Patients with Relapse or Refractory Primary Central Nervous System Lymphoma during Phase I/II Study of Tirabrutinib

Yasuhito Terui, Yoshitaka Narita, Motoo Nagane, Kazuhiko Mishima, Yoshiki Arakawa, Hajime Yonezawa, Katsunori Asai, Noriko Fukuhara, Kazuhiko Sugiyama, Naoki Shinojima, Arata Aoi, Ryo Nishikawa

Blood (2021) 138 (Supplement 1): 4561.

https://doi.org/10.1182/blood-2021-146439

Published: 2021

Journal Articles

Two -Year Follow-up Data of Phase II Study of Tirabrutinib, a Second-Generation Bruton's Tyrosine Kinase Inhibitor, in Patients with Treatment-Naïve or Relapsed/Refractory Waldenström's Macroglobulinemiatwo -Year Follow-up Data of Phase II Study of Tirabrutinib, a Second-Generation Bruton's Tyrosine Kinase Inhibitor, in Patients with Treatment-Naïve or Relapsed/Refractory Waldenström's Macroglobulinemia

Kenshi Suzuki, Naohiro Sekiguchi, Shinya Rai, Wataru Munakata, Hiroshi Handa, Hirohiko Shibayama, Tomoyuki Endo, Yasuhito Terui, Noriko Iwaki, Noriko Fukuhara, Hiro Tatetsu, Shinsuke Iida, Takayuki Ishikawa, Daisuke Iguchi, Koji Izutsu

Blood (2021) 138 (Supplement 1): 1352.

https://doi.org/10.1182/blood-2021-146744

Published: 2021

Journal Articles

Asian Multinational Phase II Study of Darinaparsin in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

Noriko Fukuhara, Won Seog Kim, Dok Hyun Yoon, Eiju Negoro, Kazuhito Yamamoto, Toshiki Uchida, Koji Izutsu, Yasuhito Terui, Hideaki Nakajima, Kiyoshi Ando, Youko Suehiro, Hye Jin Kang, Po-Shen Ko, Fumiko Nagahama, Yusuke Sonehara, Hirokazu Nagai, Hwei-Fang Tien, Yok-Lam Kwong, Kensei Tobinai

Blood (2021) 138 (Supplement 1): 1376.

https://doi.org/10.1182/blood-2021-145512

Published: 2021

Journal Articles

Cell-Free DNA Genotyping Analysis in Diffuse Large B-Cell Lymphoma; The Correlation between TP53 Gene Mutation and Cereblon Gene Mutation

Hideki Uryu, MD, Yuko Mishima, MD PhD, Yuji Mishima, PhD, Masahiro Yokoyama, MD, Noriko Nishimura, MD PhD, Yoshiharu Kusano, MD, Takashi Okabe, MD, Norihito Inoue, MD, Takanori Fukuta, MD, Yuko Shirouchi, MD, Kiyohiko Hatake, MD PhD, Yasuhito Terui, MD PhD

Blood (2019) 134 (Supplement_1): 2786.

https://doi.org/10.1182/blood-2019-122920

Published: 2019

Journal Articles

Phase 2 Study of Tirabrutinib (ONO/GS-4059), a Second-Generation Bruton's Tyrosine Kinase Inhibitor, Monotherapy in Patients with Treatment-Naïve or Relapsed/Refractory Waldenström Macroglobulinemia

Wataru Munakata, Naohiro Sekiguchi, MD PhD, Rai Shinya, MD,PhD, Kenshi Suzuki, MD PhD, Hiroshi Handa, MD PhD, Hirohiko Shibayama, MD PhD, Tomoyuki Endo, MD PhD, Yasuhito Terui, MD PhD, Noriko Iwaki, MD PhD, Noriko Fukuhara, MD PhD, Hiro Tatetsu, MD PhD, Shinsuke Iida, MD PhD, Takayuki Ishikawa, MD PhD, Ryota Shiibashi, Koji Izutsu, MD PhD

Blood (2019) 134 (Supplement_1): 345.

https://doi.org/10.1182/blood-2019-124614

Published: 2019

Journal Articles

Phase 2 Study of E7777, a Diphtheria Toxin Fragment-Interleukin-2 Fusion Protein, in Japanese Patients with Relapsed or Refractory Peripheral and Cutaneous T-Cell Lymphoma

Blood (2019) 134 (Supplement_1): 4032.

https://doi.org/10.1182/blood-2019-121723

Published: 2019

Journal Articles

The Necessary for Long-Term Follow-up of Mutated Genes and Clonal Evolutions in Multiple Myeloma Combined with cfDNA Assay

Yuko Mishima, MD PhD, Yuji Mishima, PhD, Masahiro Yokoyama, MD, Noriko Nishimura, MD PhD, Yoshiharu Kusano, MD, Norihito Inoue, MD, Hideki Uryu, MD, Takanori Fukuta, MD, Yuko Shirouchi, MD, Kiyohiko Hatake, MD PhD, Yasuhito Terui, MD PhD

Blood (2019) 134 (Supplement_1): 5515.

https://doi.org/10.1182/blood-2019-122977

Published: 2019

Journal Articles

Serum Cell-Free DNA Concentration Is Predictive of Survival Outcomes and Its Genetic Mutation Analysis May Be Viable in Obtaining Pathological Information

Yuko Shirouchi, MD, Yuko Mishima, MD PhD, Yuji Mishima, PhD, Masahiro Yokoyama, MD, Noriko Nishimura, MD PhD, Yoshiharu Kusano, MD, Hideki Uryu, MD, Takashi Okabe, MD, Norihito Inoue, MD, Takanori Fukuta, MD, Kiyohiko Hatake, MD PhD, Yasuhito Terui, MD PhD

Blood (2019) 134 (Supplement_1): 1498.

https://doi.org/10.1182/blood-2019-125096

Published: 2019

Journal Articles

Phase 1/2 Study of Tirabrutinib (ONO/GS-4059), a Next-Generation Bruton's Tyrosine Kinase (BTK) Inhibitor, Monotherapy in Patients with Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)

Motoo Nagane, MD PhD, Yoshitaka Narita, MD PhD, Kazuhiko Mishima, MD PhD, Yasuhito Terui, MD PhD, Yoshiki Arakawa, MD PhD, Hajime Yonezawa, MD PhD, Katsunori Asai, MD PhD, Noriko Fukuhara, MD PhD, Kazuhiko Sugiyama, MD PhD, Naoki Shinojima, MD PhD, Junsaku Kitagawa, Arata Aoi, Ryo Nishikawa, MD PhD

Blood (2019) 134 (Supplement_1): 1586.

https://doi.org/10.1182/blood-2019-123362

Published: 2019

Journal Articles

The Role of Image Surveillance in Patients with Diffuse Large B-Cell Lymphoma: A Single-Center Validation Study

Takanori Fukuta, MD, Noriko Nishimura, MD PhD, Yuko Shirouchi, MD, Anna Nishihara, MD, Norihito Inoue, MD, Hideki Uryu, MD, Yoshiharu Kusano, MD, Yuko Mishima, MD PhD, Naoko Tsuyama, MD PhD, Kengo Takeuchi, MD PhD, Masahiro Yokoyama, MD, Yasuhito Terui, MD PhD

Blood (2018) 132 (Supplement 1): 2989.

https://doi.org/10.1182/blood-2018-99-113984

Published: 2018

Journal Articles

Impact of Creatinine Clearance in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP : A Real-World Long-Term Observation Analysis at a Single Institute

Noriko Nishimura, MD PhD, Takanori Fukuta, MD, Anna Nishihara, MD, Yuko Shirouchi, MD, Hideki Uryu, MD, Norihito Inoue, MD, Yoshiharu Kusano, MD, Naoko Tsuyama, MD PhD, Kengo Takeuchi, MD PhD, Yuko Mishima, MD PhD, Masahiro Yokoyama, MD, Yasuhito Terui, MD PhD

Blood (2018) 132 (Supplement 1): 5399.

https://doi.org/10.1182/blood-2018-99-115897

Published: 2018

Journal Articles

The Prognostic Significance of Soluble Interleukin-2-Receptor, Beta-2-Microgrobulin and Serum Albumin in Patient with Diffuse Large B-Cell Lymphoma in the Rituximab Era

Norihito Inoue, MD, Masahiro Yokoyama, MD, Yuko Shirouchi, MD, Takanori Fukuta, MD, Anna Nishihara, MD, Yoshiharu Kusano, MD, Hideki Uryu, MD, Yuko Mishima, MD PhD, Noriko Nishimura, MD PhD, Naoko Tsuyama, MD PhD, Kengo Takeuchi, MD PhD, Yasuhito Terui, MD PhD

Blood (2018) 132 (Supplement 1): 4242.

https://doi.org/10.1182/blood-2018-99-115863

Published: 2018

Journal Articles

B-Symptoms, Performance Status and Response to First Therapy As Survival Predictive Factors for Peripheral T-Cell Lymphoma at Progression/Relapse: A Single Institute Analysis

Yuko Shirouchi, MD, Takanori Fukuta, MD, Anna Nishihara, MD, Norihito Inoue, MD, Hideki Uryu, MD, Yoshiharu Kusano, MD, Noriko Nishimura, MD PhD, Yuko Mishima, MD PhD, Masahiro Yokoyama, MD, Naoko Tsuyama, MD PhD, Kengo Takeuchi, MD PhD, Yasuhito Terui, MD PhD

Blood (2018) 132 (Supplement 1): 5360.

https://doi.org/10.1182/blood-2018-99-112038

Published: 2018

Journal Articles

The Prognosis of Transformed DLBCL Were Superior to De Novo DLBL after the Relapsed/Refractory Status Related to the MYC Translocation

Yuko Mishima, PhD, Masahiro Yokoyama, MD, Noriko Nishimura, MD PhD, Yoshiharu Kusano, MD, Hideki Uryu, MD, Norihito Inoue, MD, Anna Nishihara, MD, Takanori Fukuta, MD, Yuko Shirouchi, MD, Naoko Tsuyama, MD PhD, Kengo Takeuchi, MD PhD, Yasuhito Terui, MD PhD

Blood (2018) 132 (Supplement 1): 5417.

https://doi.org/10.1182/blood-2018-99-111081

Published: 2018

Journal Articles

Efficacy of Rituximab Maintenance for Diffuse Large B Cell Lymphoma with Transformation

Hideki Uryu, MD, Yuko Mishima, MD PhD, Masahiro Yokoyama, MD, Noriko Nishimura, MD PhD, Yoshiharu Kusano, MD, Norihito Inoue, MD, Anna Nishihara, MD, Takanori Fukuta, MD, Yuko Shirouchi, MD, Naoko Tsuyama, MD PhD, Kengo Takeuchi, MD PhD, Yasuhito Terui, MD PhD

Blood (2018) 132 (Supplement 1): 4229.

https://doi.org/10.1182/blood-2018-99-111513

Published: 2018

NARROW

A Phase 1 Trial of OPB-111077 in Combination with Bendamustine (B) and Rituximab (R) in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of Dose-Escalation Stage

Post-Hoc Analysis of the Final, Three-Year Follow-up Results of a Phase I/II Study on Tirabrutinib (ONO-4059) in Patients with Relapsed or Refractory Primary Central Nervous System Lymphoma

Mixture Model to Predict the Cumulative Incidence of Relapses in Follicular Lymphoma : Need for Longer Follow-up or Alternative Outcomes

The Seven-Color FISH Analysis Can Detect the Acquisition Pattern of Complex Chromosomal Abnormalities Related to Poor Response and Prognosis in Patients with Multiple Myeloma

Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial

Quality of Life and Karnofsky Performance Status in Patients with Relapse or Refractory Primary Central Nervous System Lymphoma during Phase I/II Study of Tirabrutinib

Asian Multinational Phase II Study of Darinaparsin in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

Cell-Free DNA Genotyping Analysis in Diffuse Large B-Cell Lymphoma; The Correlation between TP53 Gene Mutation and Cereblon Gene Mutation

Phase 2 Study of Tirabrutinib (ONO/GS-4059), a Second-Generation Bruton's Tyrosine Kinase Inhibitor, Monotherapy in Patients with Treatment-Naïve or Relapsed/Refractory Waldenström Macroglobulinemia

Phase 2 Study of E7777, a Diphtheria Toxin Fragment-Interleukin-2 Fusion Protein, in Japanese Patients with Relapsed or Refractory Peripheral and Cutaneous T-Cell Lymphoma

The Necessary for Long-Term Follow-up of Mutated Genes and Clonal Evolutions in Multiple Myeloma Combined with cfDNA Assay

Serum Cell-Free DNA Concentration Is Predictive of Survival Outcomes and Its Genetic Mutation Analysis May Be Viable in Obtaining Pathological Information

Phase 1/2 Study of Tirabrutinib (ONO/GS-4059), a Next-Generation Bruton's Tyrosine Kinase (BTK) Inhibitor, Monotherapy in Patients with Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)

The Role of Image Surveillance in Patients with Diffuse Large B-Cell Lymphoma: A Single-Center Validation Study

Impact of Creatinine Clearance in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP : A Real-World Long-Term Observation Analysis at a Single Institute

The Prognostic Significance of Soluble Interleukin-2-Receptor, Beta-2-Microgrobulin and Serum Albumin in Patient with Diffuse Large B-Cell Lymphoma in the Rituximab Era

B-Symptoms, Performance Status and Response to First Therapy As Survival Predictive Factors for Peripheral T-Cell Lymphoma at Progression/Relapse: A Single Institute Analysis

The Prognosis of Transformed DLBCL Were Superior to De Novo DLBL after the Relapsed/Refractory Status Related to the MYC Translocation

Efficacy of Rituximab Maintenance for Diffuse Large B Cell Lymphoma with Transformation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only